Monoclonal Antibodies Market Overview:
According to Cancer Research UK, around 17 million new cases of cancer and 9.6 million mortality incidences were recorded globally in 2018.  As per this statistic, the cancer threat is increasing rapidly throughout the world and safer medical treatment is being sought out over more conventional methods. Antibody vaccines effectively induce the desired medication with comparatively higher rates of success, leading to development of monoclonal antibodies (mAbs), which target a specific area or cell. Designed in laboratories with an aim to trigger the natural immune system and destroy cancer causing cells, monoclonal antibodies are a flagship innovation in the medical sector approved by the U.S. Food and Drug Administration (FDA) as an effective measure for cancer treatment. Potential benefits of monoclonal antibodies include detecting and killing abnormal cells directly, inhibiting cancer cell growth, and delivering radioactive particles or chemo drugs to the specific cells, thereby minimizing the risk of side-effects from medication while also promoting functioning of the immune system.
Proven to be effective in treatment of brain cancer, lung cancer, prostate cancer, breast cancer, and many other types, mAb therapy is attracting huge demand. Not only are mAbs being used to treat cancer, but its therapeutic use in treating ulcerative colitis, rheumatoid arthritis, asthma, Crohn’s disease, and ankylosing spondylitis is also notable. The global monoclonal antibodies market stood at $101.5 billion in 2018 owing to increasing adoption of mAbs throughout the world. Due to the ever-increasing population and incidences of cancer, the mAbs market is expected to grow at a CAGR of 8.51% through to 2025.
Monoclonal Antibodies Market Outlook:
The advent of monoclonal antibodies hybridoma technology, and production of mAbs in large quantities in accordance with targeted antigens of defective cells, opened up wider avenues for biochemistry, molecular biology, and medicine. Mounting demand influenced by growing medico-technological advancements will contribute to the European mAbs market. Currently, Europe is the fastest growing mAbs market owing to colossal expenditure in biomedical engineering brought about by increasing health risks, which culminated in the region holding a market share of 42.30% in 2018. Administered intravenously, mAb vaccinations are sought after across the world because they cause no adverse effects on the peripheral area, which was proved through successful experimental trials. Monoclonal antibodies market is majorly fueled by the oncology segment, projected to increase at a CAGR of 8.67% and expand with lucrative revenue in the foreseeable years.
Monoclonal Antibodies Market Growth Drivers:
· Increasing incidences of cancer, autoimmune diseases, infectious diseases, inflammatory diseases, and microbial diseases have a contributory role in generating huge demand for mAb therapy.
· Homogeneity of mAbs makes them suitable for experimental procedures also since they can facilitate production of identical antibodies. Thus, they are able to keep up with the increasing requirements of the healthcare industry.
· Unlimited production and specific clone identification with respect to a particular antigen make it a unique product engineered with ease in laboratories.
Monoclonal Antibodies Market Challenges:
Certain issues that arise during manufacturing of mAbs include the cost-inefficient procedure and susceptibility towards contamination during the hybridoma culture. Furthermore, production requires additional cell culture and purification procedures for successfully yielding mAbs. Key companies in the sector are attempting to overcome these challenges by conducting extensive research.
Monoclonal Antibodies Market Key Players:
The major companies leading the global monoclonal antibodies market include Johnson & Johnson Services, Inc., Amgen Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Abbott Laboratories, AstraZeneca, Eli Lilly and Company, Mylan N.V., Thermo Fisher Scientific, Daiichi Sankyo Company, Ltd., Bayer AG, Merck & Co., Inc, Biogen Inc., Sanofi Genzyme, GlaxoSmithKline plc, Novo Nordisk A/S, Bristol Myers Squibb Co., and others.
GlaxoSmithKline plc is a multinational pharmaceutical company manufacturing vaccines and healthcare products. One of their major achievements in 2018 involves vending 770 million doses of vaccines.
Monoclonal Antibodies Market Trends:
· Metastatic Cancer Treatment:
The second highest cause of death, cancer has been around for more than a thousand years. Dating back to the ancient Greek civilization, cancer trauma has compelled important discoveries and scientific innovations globally. One of the major breakthroughs is the introduction of mAbs for treating advanced and metastatic cancers. Earlier, metastatic tumors had no actual treatment procedures but therapeutic approaches of mAbs have accomplished significant results in modern times.
Monoclonal Antibodies Market Research Scope:
The base year of the study is 2018, with forecast done up to 2025. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. It also provides information on unit shipments. These provide the key market participants with the necessary business intelligence and help them understand the future of the monoclonal antibodies market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats. The key areas of focus include the types of monoclonal antibodies in monoclonal antibodies market, and their specific applications in different areas.
Monoclonal Antibodies Market: Industry Coverage:
Global monoclonal antibodies market has only one segmentation which is application. Categorization based on application includes oncology, autoimmune and inflammatory diseases, respiratory diseases and ophthalmology.
The monoclonal antibodies market also analyzes the major geographic regions for the market as well as the major countries for the market in these regions. The regions and countries covered in the study include:
• North America: The U.S., Canada, Mexico
• South America: Brazil, Venezuela, Argentina, Ecuador, Peru, Colombia, Costa Rica
• Europe: The U.K., Germany, Italy, France, The Netherlands, Belgium, Spain, Denmark
• APAC: China, Japan, Australia, South Korea, India, Taiwan, Malaysia, Hong Kong
• Middle East and Africa: Israel, South Africa, Saudi Arabia